Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?

作     者：Mehmet Ali Nahit Sendur Nuriye Yildirim zdemir Muhammed Bülent Akinci Dogan Uncu Nurullah Zengin Sercan Aksoy 

作者机构：Department of Medical OncologyAnkara Numune Education and Research HospitalAnkara 06100Turkey Department of Medical OncologyHacettepe University Institute of OncologyAnkara 06100Turkey 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第1期

页      面：144-146页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Imatinib Gastrointestinal stromal tumor Activating mutation Stem cell factor receptor Platelet-derived growth factor receptor alpha Mutation analysis 

摘      要：Gastrointestinal stromal tumors(GISTs) are the most common soft tissue sarcoma of the gastrointestinal tract,resulting from an activating mutation of stem cell factor receptor(KIT),and an activating mutation of the homologous platelet-derived growth factor receptor alpha(PDGFRA) *** GISTs(90%-95%) are *** 5% of GISTs are truly negative for KIT *** have been documented to resistant conventional *** to the KIT activation that occurs in the majority of the cases,KIT inhibition is the primary treatment approach in the adjuvant treatment of metastatic *** mesylate is an oral agent that is a selective protein tyrosine kinase inhibitor of the KIT protein tyrosine kinase,and it has demonstrated clinical benefit and objective tumor responses in most GIST patients in phase Ⅱ and Ⅲ *** presence and the type of KIT or PDGFRA mutation are predictive of response to imatinib therapy in patients with advanced and metastatic *** analysis in phaseⅠ-Ⅱ trials revealed significant differences in objective response,progression-free survival,and overall survival between GISTs with different kinase *** aim of this letter is to touch on the need for exon mutation analysis for adjuvant treatment with imatinib in GIST patients.